donepezil has been researched along with Psychomotor Agitation in 14 studies
Donepezil: An indan and piperidine derivative that acts as a selective and reversible inhibitor of ACETYLCHOLINESTERASE. Donepezil is highly selective for the central nervous system and is used in the management of mild to moderate DEMENTIA in ALZHEIMER DISEASE.
donepezil : A racemate comprising equimolar amounts of (R)- and (S)-donepezil. A centrally acting reversible acetylcholinesterase inhibitor, its main therapeutic use is in the treatment of Alzheimer's disease where it is used to increase cortical acetylcholine.
2-[(1-benzylpiperidin-4-yl)methyl]-5,6-dimethoxyindan-1-one : A member of the class of indanones that is 5,6-dimethoxyindan-1-one which is substituted at position 2 by an (N-benzylpiperidin-4-yl)methyl group.
Psychomotor Agitation: A feeling of restlessness associated with increased motor activity. This may occur as a manifestation of nervous system drug toxicity or other conditions.
| Excerpt | Relevance | Reference |
|---|---|---|
| "To investigate the behavioral effects of memantine in moderate to severe Alzheimer disease (AD)." | 9.12 | Behavioral effects of memantine in Alzheimer disease patients receiving donepezil treatment. ( Cummings, JL; Graham, SM; Schneider, E; Tariot, PN, 2006) |
| "To investigate the behavioral effects of memantine in moderate to severe Alzheimer disease (AD)." | 5.12 | Behavioral effects of memantine in Alzheimer disease patients receiving donepezil treatment. ( Cummings, JL; Graham, SM; Schneider, E; Tariot, PN, 2006) |
| " Symptoms, interventions, and treatment-related adverse events addressed in this issue are management of Alzheimer's agitation with donepezil; needle-free lidocaine powder for minor painful procedures; psychostimulants in depression; anticoagulation for cancer-related venous thromboembolism; effect of waiting for acute pain treatment on risk of chronic pain; and an update on severe cutaneous reactions associated with medications." | 4.85 | Pain and palliative care pharmacotherapy literature summaries and analyses. ( Abernethy, AP; Farrell, TW, 2009) |
| "Participants had probable or possible Alzheimer's disease, were resident in a care home, had clinically significant agitation (defined as a score of 39 or above on the Cohen Mansfield Agitation Inventory) and were free of antipsychotics and/or anticholinesterase for at least 2 weeks." | 2.76 | A double-blind placebo-controlled randomized trial of Melissa officinalis oil and donepezil for the treatment of agitation in Alzheimer's disease. ( Ballard, C; Burns, A; Chazot, P; Francis, P; Holmes, C; Howes, MJ; Lees, G; Morris, J; Perry, E, 2011) |
| " An unexpectedly large placebo effect, inadequate dosage (mean 120 mg/day), and inadequate power may have contributed to lack of demonstrable benefit." | 2.73 | Quetiapine for agitation or psychosis in patients with dementia and parkinsonism. ( Cummings, J; Kurlan, R; Raman, R; Thal, L, 2007) |
| "We randomly assigned 272 patients with Alzheimer's disease who had clinically significant agitation and no response to a brief psychosocial treatment program to receive 10 mg of donepezil per day (128 patients) or placebo (131 patients) for 12 weeks." | 2.73 | Donepezil for the treatment of agitation in Alzheimer's disease. ( Ballard, CG; Bentham, P; Brown, RG; Bullock, R; Burns, AS; DeCesare, J; Holmes, C; Howard, RJ; Jacoby, R; Johnson, T; Jones, RW; Juszczak, E; Katona, C; Knapp, M; Lindesay, J; O'Brien, JT; Rodger, M; Wilcock, G, 2007) |
| "Treatment with donepezil and rivastigmine (successively) did not produce the desired benefits." | 1.32 | A case study in the treatment of dementia with Lewy bodies. ( Kaufer, DI, 2004) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 10 (71.43) | 29.6817 |
| 2010's | 4 (28.57) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Naharci, MI | 1 |
| Kimura, T | 1 |
| Takamatsu, J | 1 |
| Abernethy, AP | 1 |
| Farrell, TW | 1 |
| Ballard, C | 2 |
| Brown, R | 1 |
| Fossey, J | 1 |
| Douglas, S | 1 |
| Bradley, P | 1 |
| Hancock, J | 1 |
| James, IA | 1 |
| Juszczak, E | 2 |
| Bentham, P | 2 |
| Burns, A | 2 |
| Lindesay, J | 2 |
| Jacoby, R | 2 |
| O'Brien, J | 1 |
| Bullock, R | 2 |
| Johnson, T | 2 |
| Holmes, C | 3 |
| Howard, R | 1 |
| Kinoshita, T | 1 |
| Hanabusa, H | 1 |
| Perry, E | 1 |
| Francis, P | 1 |
| Morris, J | 1 |
| Howes, MJ | 1 |
| Chazot, P | 1 |
| Lees, G | 1 |
| Kaufer, DI | 1 |
| Cummings, JL | 1 |
| Schneider, E | 1 |
| Tariot, PN | 1 |
| Graham, SM | 1 |
| Logan, CJ | 1 |
| Stewart, JT | 1 |
| Kurlan, R | 1 |
| Cummings, J | 1 |
| Raman, R | 1 |
| Thal, L | 1 |
| Howard, RJ | 1 |
| Ballard, CG | 1 |
| Brown, RG | 1 |
| Burns, AS | 1 |
| Knapp, M | 1 |
| O'Brien, JT | 1 |
| Wilcock, G | 1 |
| Katona, C | 1 |
| Jones, RW | 1 |
| DeCesare, J | 1 |
| Rodger, M | 1 |
| Yaffe, K | 1 |
| Kwak, YT | 1 |
| Han, IW | 1 |
| Baik, J | 1 |
| Koo, MS | 1 |
| Skjerve, A | 1 |
| Nygaard, HA | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Enhanced Care Home Outcomes (ECHO): An Evaluation of the Experiences of Staff and Stakeholders Working With an Integrated Care Home Support Service (CHSS)[NCT02703792] | 19 participants (Actual) | Observational | 2016-03-31 | Completed | |||
| A Randomised Placebo Controlled Trial of a Cholinesterase Inhibitor in the Management of Agitation in Dementia That is Unresponsive to a Psychological Intervention[NCT00142324] | Phase 4 | 190 participants | Interventional | 2003-11-30 | Active, not recruiting | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
2 reviews available for donepezil and Psychomotor Agitation
| Article | Year |
|---|---|
Pain and palliative care pharmacotherapy literature summaries and analyses.
Topics: Alzheimer Disease; Amphetamines; Anesthetics, Local; Anticoagulants; Antidepressive Agents; Depressi | 2009 |
Issues facing home-based medical support services.
Topics: Aged; Aged, 80 and over; Antipsychotic Agents; Caregivers; Delirium; Dementia; Diagnosis, Differenti | 2010 |
5 trials available for donepezil and Psychomotor Agitation
| Article | Year |
|---|---|
Brief psychosocial therapy for the treatment of agitation in Alzheimer disease (the CALM-AD trial).
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Cholinesterase Inhibitors; Donepezil; Female; Homes for | 2009 |
A double-blind placebo-controlled randomized trial of Melissa officinalis oil and donepezil for the treatment of agitation in Alzheimer's disease.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Aromatherapy; Cholinesterase Inhibitors; Data Interpreta | 2011 |
Behavioral effects of memantine in Alzheimer disease patients receiving donepezil treatment.
Topics: Activities of Daily Living; Aged; Aged, 80 and over; Alzheimer Disease; Antiparkinson Agents; Behavi | 2006 |
Quetiapine for agitation or psychosis in patients with dementia and parkinsonism.
Topics: Activities of Daily Living; Aged; Aged, 80 and over; Alzheimer Disease; Antiparkinson Agents; Antips | 2007 |
Donepezil for the treatment of agitation in Alzheimer's disease.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Cholinesterase Inhibitors; Donepezil; Double-Blind Metho | 2007 |
7 other studies available for donepezil and Psychomotor Agitation
| Article | Year |
|---|---|
Could delirium and anti-dementia drugs effect the treatment of agitated nursing home residents with Alzheimer dementia?
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Cholinesterase Inhibitors; Cohort Studies; Delirium; Don | 2018 |
Pilot study of pharmacological treatment for frontotemporal dementia: risk of donepezil treatment for behavioral and psychological symptoms.
Topics: Apathy; Behavioral Symptoms; Delusions; Donepezil; Follow-Up Studies; Frontotemporal Dementia; Human | 2013 |
A case study in the treatment of dementia with Lewy bodies.
Topics: Aged; Aged, 80 and over; Carbamates; Cognition Disorders; Donepezil; Drug Resistance; Female; Galant | 2004 |
Treatment of post-electroconvulsive therapy delirium and agitation with donepezil.
Topics: Aged; Cholinesterase Inhibitors; Delirium; Depressive Disorder, Major; Donepezil; Electroconvulsive | 2007 |
Treatment of neuropsychiatric symptoms in patients with dementia.
Topics: Aged; Alzheimer Disease; Antipsychotic Agents; Cholinesterase Inhibitors; Donepezil; Humans; Indans; | 2007 |
Relation between cholinesterase inhibitor and Pisa syndrome.
Topics: Aged; Alzheimer Disease; Carbamates; Cholinesterase Inhibitors; Donepezil; Dopamine Antagonists; Dys | 2000 |
Improvement in sundowning in dementia with Lewy bodies after treatment with donepezil.
Topics: Aged; Cholinesterase Inhibitors; Circadian Rhythm; Donepezil; Humans; Indans; Lewy Body Disease; Mal | 2000 |